1. Home
  2. ANNX vs FNLC Comparison

ANNX vs FNLC Comparison

Compare ANNX & FNLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • FNLC
  • Stock Information
  • Founded
  • ANNX 2011
  • FNLC 1864
  • Country
  • ANNX United States
  • FNLC United States
  • Employees
  • ANNX N/A
  • FNLC N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • FNLC Major Banks
  • Sector
  • ANNX Health Care
  • FNLC Finance
  • Exchange
  • ANNX Nasdaq
  • FNLC Nasdaq
  • Market Cap
  • ANNX 263.3M
  • FNLC 284.0M
  • IPO Year
  • ANNX 2020
  • FNLC 1999
  • Fundamental
  • Price
  • ANNX $2.56
  • FNLC $25.82
  • Analyst Decision
  • ANNX Strong Buy
  • FNLC
  • Analyst Count
  • ANNX 4
  • FNLC 0
  • Target Price
  • ANNX $12.50
  • FNLC N/A
  • AVG Volume (30 Days)
  • ANNX 1.8M
  • FNLC 26.6K
  • Earning Date
  • ANNX 08-11-2025
  • FNLC 07-23-2025
  • Dividend Yield
  • ANNX N/A
  • FNLC 5.60%
  • EPS Growth
  • ANNX N/A
  • FNLC 1.61
  • EPS
  • ANNX N/A
  • FNLC 2.52
  • Revenue
  • ANNX N/A
  • FNLC $82,116,000.00
  • Revenue This Year
  • ANNX N/A
  • FNLC N/A
  • Revenue Next Year
  • ANNX N/A
  • FNLC N/A
  • P/E Ratio
  • ANNX N/A
  • FNLC $10.31
  • Revenue Growth
  • ANNX N/A
  • FNLC 5.28
  • 52 Week Low
  • ANNX $1.29
  • FNLC $22.11
  • 52 Week High
  • ANNX $7.85
  • FNLC $31.05
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 54.40
  • FNLC 57.54
  • Support Level
  • ANNX $1.85
  • FNLC $25.44
  • Resistance Level
  • ANNX $2.97
  • FNLC $27.58
  • Average True Range (ATR)
  • ANNX 0.27
  • FNLC 0.66
  • MACD
  • ANNX 0.00
  • FNLC 0.12
  • Stochastic Oscillator
  • ANNX 60.32
  • FNLC 60.05

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

Share on Social Networks: